Matthew S. Davids, MD, on Sequence of Administration of Ibrutinib Plus Obinutuzumab for CLL

Posted: Saturday, September 12, 2020

Matthew S. Davids, MD, of Dana-Farber Cancer Institute, discusses phase Ib data showing that obinutuzumab incidence rate ratios in relapsed or refractory chronic lymphocytic leukemia were higher with obinutuzumab started prior to ibrutinib, compared with starting ibrutinib prior to obinutuzumab or starting both drugs simultaneously.